Harmony Baby Nutrition is building next generation pediatric formulas, offering the closest match to human milk, ever by using human milk components.

Led by a repeat founder in the infant nutrition space and supported by world-renowned pediatric and regulatory experts from Harvard, Mass General, Pfizer, Gerber, and Nestlé, Harmony is creating a superior alternative in a $100B+ market ripe for disruption.

With $13.5M raised from top VCs and grants, we’ve completed rigorous R&D and are now entering the market with our first product, an allergy-friendly toddler formula. We will then expand to a broader range of revolutionary infant formula products all built on the same clean-label, human milk foundation.

At Harmony, we believe the 130M+ infants and toddlers worldwide who rely on formula shouldn’t have to compromise. By redesigning formula around human milk components, we’re creating products that parents, babies, and physicians love – because they are designed to closely replicate the form and function of human milk, while tasting great - giving the next generation the best possible start in life.

Infant formula was invented more than 100 years ago, yet its evolution has been minimal, limited to incremental changes and the addition of a few new ingredients.

Most formulas still rely on cow’s milk as the core ingredient, whose proteins were never intended for the human immune or digestive system. While these products provide calories and the basic nutrition, they lack the bioactive components essential for gut development and immune programming.

Decades of research has proven that human milk is far more complex and serves many purposes that cow’s milk alone will never meet.

Formula is a critical life line for millions of infants. By six months old, about 90% of babies in the U.S. rely on formulas when human milk is not available. Globally, more than 50% of infants consume formula at some stage.

Yet 1 in 5 babies cannot tolerate standard formula made with cow’s milk. They suffer from inflammation, digestive distress, and stressful feeding cycles during the most critical months of development.

When standard formulas fail, parents turn to hypoallergenic options that strip out allergenic proteins. What’s left is often formulas that smell awful, taste bitter and are packed with industrially added sugars - leading many babies to reject them.

For many families, feeding becomes a daily fight. Parents persist because they have no other choice.

Until now, no formula addresses both the nutrition gap and the function gap between formula and human milk.

Enter Harmony. We’re transforming the $100B+ global infant nutrition market by designing formulas that mirror human milk in both form and function.

Harmony is at the forefront of cutting-edge formulation science.

We source best-in-class, human-milk-inspired components, key human milk oligosaccharides (HMOs), and essential fatty acids found in breast milk.

We then apply deep formulation science and product development expertise to assemble them into infant nutrition that is stable, safe, effective and enjoyable.

We use lactose as the primary carbohydrate because it’s actually the main ingredient in human milk. Babies are actually really good at digesting lactose. Lactose intolerance, a rare disease, does not develop until adulthood.

Instead of removing allergens from cow’s milk, breaking down components further and further, Harmony designs an entirely new formulation matrix built around human milk–like components and how they behave together in a real product.

That’s what allows our formulas to be both hypoallergenic and drinkable - a combination the category has struggled to achieve for decades.

Harmony is scaling an infant nutrition platform, not a single product. Our patented technology enables a clear product pipeline: we enter through a high-need, high-margin hypoallergenic (HA) market, then expand into the broader routine infant nutrition category. Each product builds on the same core, human-milk-inspired foundation, allowing us to scale efficiently from niche to mass market.

The first generation of products we’re bringing to market, our allergy-friendly toddler formula Melodi, is launching in 2026.

We’re beginning with toddler nutrition in an underserved category because of the lower barriers to entry. This early product will also allow us to validate our approach and build trust with parents and healthcare providers.

Melodi benefits from FDA clearance because we are using approved ingredients and targeting toddlers. Our next step will be to show safety for babies 0 to 12 months via a clinical trial.

From this foundation, we will then expand into the broader infant market with bioactive, human-milk inspired compositions, all built on the same formulation platform.

Our pipeline includes extensively hydrolysed formulas and amino acid formulas, and a roadmap to launch several revolutionary infant formula products, all built on the same clean-label, taste-forward, human milk–inspired foundation.

With Harmony, parents don’t need to cycle through multiple formulas when human milk is not available. Our suite of products are designed to work from birth, reducing feeding uncertainty for all babies during the most critical months of life.

Harmony is developed in partnership with the experts who shape infant nutrition. We collaborate with leaders in pediatric allergy, immunology, and nutrition from Harvard/Massachusetts General Hospital, UC Davis, Baylor College of Medicine, and the University of Rochester.

Clinicians are seeing rising rates of infant allergies with few nutritional options that balance tolerance and development. 50% of pediatricians we spoke with said they prefer Harmony’s new concept over well known brands.

Harmony gives pediatricians a credible alternative they can confidently recommend.

Melodi was designed to improve acceptance and to lead the sustained use during key developmental months.

Harmony is led by a repeat founder with over 20 years of experience in infant nutrition, having launched more than 30 science-backed products and supported thousands of babies with dietary restrictions.

Our team brings deep operating experience alongside former Nestlé and Gerber regulatory and manufacturing leaders and world-renowned pediatric allergy and nutrition experts from leading medical institutions like Massachusetts General and Harvard Medical.

Together, we bring a rare combination of scientific depth and proven execution required to build a global category-defining infant nutrition company.

Infant nutrition is a $100B+ global market driven by essential and recurring consumption. In the U.S., more than 90% of babies consume formula by six months, either exclusively or as a supplement.

Within this market, hypoallergenic formula represents one of the most critical segments, serving up to 17% of infants that experience acute food allergy symptoms such as Food Protein-Induced Allergic Proctocolitis (FPIAP). It is a high-urgency category driven by medical necessity, where increasing pediatric awareness and earlier diagnosis are pushing families into hypoallergenic formulas sooner and for longer periods of time. The result is a fast-growing segment where parents are actively seeking better solutions.

Harmony is also creating an entirely new category in this market: functional formula.

Harmony operates in a sticky, repeat-purchase category where brand loyalty is high. With hypoallergenic formulas in particular, once tolerance is established, parents rarely switch products.

Usage is daily, predictable, and often medically guided, resulting in strong retention, high lifetime value, and meaningful switching costs.

Early data supports the strength of our model. Customers purchase at a premium price point of approximately $50 per can, consume at expected clinical volumes, and remain on product for multiple months, generating more than $2,400 in lifetime value per customer.

These unit economics apply to the entire suite of our product roadmap, from the hypoallergenic toddler product to bioactive baby formulas.

We’re projecting over $7M in sales purely from our Gen 1 products by 2029. However the full enterprise value of Harmony at that point will be much greater as we get closer to bringing our Gen 2 and Gen 3 products to market in late 2029 and 2030.

The pharmaceutical-grade innovative nature of these later stage products serves as both a competitive moat and significant value driver as we reach key clinical and regulatory milestones and accumulate more IP.

Infant and medical nutrition is one of the most proven exit categories in consumer health, with multiple multi-billion-dollar acquisitions by global leaders like Nestlé, Danone, and Reckitt. These outcomes demonstrate sustained M&A appetite for differentiated infant and pediatric nutrition assets at scale.

With patented, human-milk-inspired technology, a scalable product platform, and entry through a high-need hypoallergenic segment, Harmony Baby Nutrition has multiple potential exit paths, including strategic acquisition by global infant nutrition or medical nutrition leaders as the platform expands.

Harmony Baby Nutrition is leading the next generation of infant nutrition in a massive $100B+ market - bringing biotechnology to the baby aisle to help the next generation thrive, not just survive.

We’re raising on Wefunder to give parents, clinicians, and mission-aligned investors the opportunity to own a stake in a company redefining baby formula, alongside top-tier backers including SOSV, Safar Partners, Rethink, and MassVentures.

Your investment will help us scale production and showcase how science development can change the game in infant nutrition.

Together, we can give millions of babies and toddlers clean nutrition as close to human milk as possible.

Join us in reshaping the future of pediatric nutrition.

wefunder.com/harmonybabynutrition